A Marseille-based company building robots to prepare teeth for veneers has closed a €15 million Series A round, betting that dentists will eventually trust machines to handle delicate cosmetic work under their supervision.
Lupin Dental announced the funding on August 28, 2026, led by Fynveur, a Luxembourg investment vehicle tied to the Invus and Artal capital groups. Fynveur committed €10 million of the total, with existing shareholders and new private investors filling out the rest, according to EU-Startups. The French startup also secured an undisclosed loan from Bpifrance, the state-backed development bank, RoboActu reported.
The deal marks a fresh vote of confidence in robotic dentistry, a niche but growing corner of medical automation. The global market for dental robotics is projected to reach roughly $880 million in 2026 and could triple to $2.8 billion by 2034, according to an OG Analysis estimate cited by Research & Markets. Whether patients will embrace the technology remains an open question.
Lupin's system combines software that maps out a desired smile with a robotic arm that mills down tooth enamel for veneer placement. The dentist oversees the process but doesn't perform the precision grinding manually, according to the company's materials. Tech Funding News described the platform as automating veneer prep while keeping clinicians in the decision-making loop.
As of the end of 2025, the system had been used on 40 patients and prepared 220 teeth across two university settings, the company said in a LinkedIn post. A small prospective study involving 12 patients and 52 teeth appeared in PubMed records in October 2025, though clinical validation remains limited compared to more established surgical robots.
Regulatory progress has been incremental. Lupin received UKCA certification on June 18, 2026, authorizing sales in Great Britain. The device lacks approval in the United States or the broader European Union, according to Tech Funding News and RoboActu. That gap explains the company's push into emerging markets: Lupin announced its first commercial installation at Pharande Dental Hospital in Pune, India, in November 2025. The system is distributed there under the brand "Dolphin Robotic Dental System" through Dolphin Lifesciences.
A month earlier, Lupin signed a memorandum of understanding with Smile-Link Healthcare Global Berhad to deploy the robot in Malaysian clinics under a pay-per-case arrangement. Patients would be charged RM16,000 per procedure over a five-year contract term, according to a company release dated November 21, 2025.
The Series A proceeds will finance additional clinical trials, manufacturing scale-up, and partnerships with universities, medical centers, and dental service organizations, RoboActu and Tech Funding News reported. Lupin declined to disclose its post-money valuation.
Invus, the investment firm advising Fynveur, will take a board seat. Fynveur itself appears in joint SEC filings alongside Artal International and Invus Public Equities, reflecting a complex cross-border capital structure. Michel Mayer chairs Lupin's board. Philippe Véran, founder of Biotech Dental, joined as a director in February.
The company was founded in 2019 by Dr. Galip Gürel and Dr. Stéfen Koubi, both aesthetic dentistry specialists. Paul Roberts, a medtech executive profiled at LSI Europe in late 2025, runs day-to-day operations as CEO. The startup employed 43 people as of its most recent LinkedIn update, though that figure may have shifted since the funding closed.
Lupin faces competition from Neocis, whose Yomi system for dental implant surgery holds FDA clearance, and Perceptive, a Boston outfit working on fully automated restorative robotics. The race centers on who can convince regulators and practitioners that machines can handle millimeter-level precision in a patient's mouth without introducing new risks.
"Lupin Dental opens a new chapter with this important milestone," Gürel and Koubi told EU-Startups, offering the kind of measured optimism common in funding announcements. Whether that chapter includes broader regulatory wins in Europe and the U.S. will determine how quickly the technology moves from universities to mainstream dental offices.
